QR Kod

Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China

Abstract Background Cyclin‐dependent kinase (CDK) 4/6 inhibitor plus endocrine therapy (ET) become standard‐of‐care for patients with hormone receptor‐positive, human epidermal growth factor receptor‐2 negative (HR+/HER2−) metastatic breast cancer (MBC). However, the optimal therapeutic paradigm aft...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Hanfang Jiang, Jianxin Zhong, Jing Wang, Guohong Song, Lijun Di, Bin Shao, Ruyan Zhang, Yaxin Liu, Anjie Zhu, Nan Wang, Huiping Li
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wiley 2024-05-01
Seri Bilgileri:Cancer Medicine
Konular:
abemaciclib
chemotherapy
endocrine therapy
hormone receptor‐positive
metastatic breast cancer
palbociclib progression
Online Erişim:https://doi.org/10.1002/cam4.7249
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller